-
Clinical Trial Exploring Psilocybin Therapy As A Treatment For Alcohol Use Disorder Achieves New Milestone
Monday, March 20, 2023 - 8:09am | 402Read More...Clairvoyant Therapeutics announced that the first clinical trial participant in Finland enrolled in CLA-PSY-201 has received their first dose of the drug along with motivational enhancement therapy. CLA-PSY-201 is the company's placebo-controlled, randomized, multi-site phase 2b trial exploring...
-
Origin Therapeutics Attaches Clairvoyant To Its Portfolio, Fueling Fast Market Strategy For Psilocybin Therapy
Thursday, July 7, 2022 - 4:10pm | 363Read More...Psychedelics investment issuer Origin Therapeutics Holdings Inc. has added Canadian biotech psychedelics developer Clairvoyant Therapeutics to its portfolio. The company’s clinical strategy is designed to enable psilocybin therapy in the European Union, UK and Canada for patients...
-
Cannabis Movers & Shakers: Clairvoyant Therapeutics, Eaze, Leafly, Chalice Brands
Monday, October 11, 2021 - 11:07am | 1007Read More...As Benzinga Cannabis Capital Conference returns in a live format this coming week (Oct. 14-15) in New York City, gathering top CEOs, investors, and leaders in the cannabis industry, let’s scroll through the latest leadership changes within the space. Psychedelics-Focused...
